2.1 Human urine stem cells were cultured, amplified and identified. According to the results in Fig. 1, urine stem cells expressed CD44 and CD90, but did not express CD45, which was consistent with the stem cell characteristics of urine stem cells in the literature. Then the cell viability of human urine stem cells was tested, as shown in Table 1 and Fig. 2. The cell viability was GOod. On day 2, day 4 and day 6, the P3 generation cells were observed after the resuscitation of different urine cells, and open-field photos were taken at 40 and 100 times. The urine stem cells were mainly adherent and most of them were spindle shaped. Open field photos were taken for 4 x and 10x at upper, lower, left, right and center positions to record the growth of cells after resuscitated. Cell shapes included: round, diamond, spindle and polyGOn cell number. Refraction: GOod; Color: clear; 3. Size, as of a grain of rice; Shape :(spherical, spindle, triangular). Description of cell growth status (adherent shape): pinnate expansion; Less spherical adhesion; Aggregate growth; Length of protuberance (half of cell body); Outgrowth: More outgrowth on both sides, but also on one side. It can be seen from Fig. 3that the cell shape is mainly fusiform. In addition, there are round cells, which may be incomplete or in bad condition.
Table 1
Cell viability test results
Cell viability test results
|
Total cell concentration
|
7.18E + 05
|
Living cell concentration
|
6.96E + 04
|
Dead cell concentration
|
2.22E + 04
|
Live cell rate
|
96.91%
|
Mean cell size
|
14.19um
|
The dilution ratio
|
2
|
Cell agglomeration rate
|
2.105%
|
2.2 Behavioral mNSS score
In order to verify the success of modeling, mNSS neurobehavioral evaluation was performed on the sham group, BI group and BI + USCs + LV group on 1, 3, 5, 7, 10, 14 and 21 days after surgery, respectively. SPSS was used for analysis, univariate measurement anOVA was used for statistics and mapping, and the results were as follows: On day 1, compared with the SHAM group, the neurological function of THE BI rats was significant. After injection of human urine stem cells into the lateral ventricle, the neurological function injury of the BI + USCs = LV group was higher than that of the BI group, P = 0.028, which was statistically significant. On day 14, compared with the SHAM group, the neurological function of THE BI rats was significant. After injection of human urine stem cells into the lateral ventricle, the neurological function injury of the BI + USCs = LV group was lower than that of the BI group (P = 0.028), which was statistically significant. The results of repeated measurement variance analysis were as follows: Repeated measurement ANOVA was used for analysis and sphericity test, and the results were P = 0.000, < 0.05. The data did not meet the sphericity hypothesis. Referring to the correction results of Greenhouse-Geisler, the results showed that both time and time*group had P < 0.05, suggesting differences in each time indicator variable. And the effect of treatment factors on index variables will change with the time. The comparison between groups and the test of inter-subject effect gives ANOVA of the treatment factor groups. P < 0.001indicated that there was a difference in the amount of difference between different treatment groups. As shown in Fig. 4 and Table 2:
Table 2
Repeat measure ANOVA table
Repeat measure ANOVA table
|
Variables
|
DF
|
SS
|
MF
|
F
|
P
|
Intervene
|
2
|
2306.271
|
1153.136
|
233.912
|
༜0.001
|
Intergroup error
|
20
|
98.596
|
4.930
|
|
|
Time
|
2.943
|
141.833
|
48.193
|
91.143
|
༜0.001
|
Time*Intervene
|
5.886
|
32.503
|
5.522
|
10.443
|
༜0.001
|
Repeated measurement
|
58.861
|
31.123
|
0.529
|
|
|
Note: DF is the degree of freedom, SS is the sum of squares, MF is the mean square and P is the significance P-value.
2.3 The effect of urine stem cell transplantation on cerebral ischemia-reperfusion was verified by bioassay. A total of 1493 genes were detected in Genecars for cerebral ischemia reperfusion. Some genes are shown in Table 3:
Table 3
Some gene targets of cerebral ischemia reperfusion
Some gene targets of cerebral ischemia reperfusion
|
APP
|
CBS
|
KCNJ5
|
CASP1
|
NTRK2
|
TSPO
|
ARID1B
|
F8
|
KRIT1
|
SLC1A2
|
ADM
|
F13A1
|
CTSD
|
HTRA2
|
LPL
|
IGFBP3
|
CST3
|
HMOX1
|
ODC1
|
ATP1A2
|
ITPR1
|
SLC9A1
|
EDNRA
|
IL12A
|
F2
|
MMP9
|
CYCS
|
AIFM1
|
FGB
|
GPT
|
EDNRB
|
CCL3
|
IL6
|
SELE
|
PDGFB
|
ANGPT1
|
HGF
|
SLC6A4
|
SMAD4
|
CCL5
|
TNF
|
EPO
|
NFE2L2
|
APOB
|
TLR2
|
CSF1R
|
RELA
|
HSPB6
|
NOS3
|
SELP
|
MAP2
|
PARP1
|
FOS
|
PF4
|
TGFBR1
|
AIF1
|
COL4A1
|
S100B
|
NPPA
|
FAS
|
HSPA8
|
PTGS1
|
ADA
|
CHAT
|
ACE
|
SOD2
|
TEK
|
CSF3
|
MIR146A
|
PRKCE
|
MIR155
|
OCLN
|
F5
|
JAK2
|
TSC2
|
HSPA1A
|
PPARG
|
PRKAA2
|
ACTB
|
CTSL
|
NOS2
|
MIR21
|
CASP9
|
AQP4
|
GLUL
|
TOMM40
|
DRD2
|
HMGCR
|
ENG
|
SERPINE1
|
GJA1
|
SLC6A3
|
CD40LG
|
MIR34A
|
TIMP3
|
PARK7
|
SOD1
|
CXCL8
|
FLT1
|
SPTAN1
|
DLG4
|
PDP1
|
MIR145
|
SPP1
|
MTHFR
|
THBD
|
PON1
|
G6PD
|
EPRS1
|
REN
|
PIK3CG
|
MCU
|
ICAM1
|
CAT
|
HSPA5
|
VCAM1
|
NPY
|
PTK2B
|
CDKN2A
|
ACTG1
|
PIK3CA
|
VWF
|
AKT1
|
LTA
|
SLC1A1
|
HP
|
PPARA
|
CACNA1B
|
MPO
|
HSPA4
|
SHH
|
MPL
|
MIR210
|
SELL
|
NLRP3
|
ABCB1
|
GAD1
|
ALB
|
SNCA
|
CR1
|
LMNA
|
ADORA3
|
CDON
|
MIR126
|
TP53
|
MB
|
GRIN1
|
ACHE
|
PECAM1
|
TNFRSF1A
|
AGER
|
AVP
|
VEGFA
|
GRIN2B
|
AGTR1
|
ADORA1
|
ATM
|
IL17A
|
FN1
|
PRKN
|
PTEN
|
TGFB2
|
MAPK14
|
CALR
|
ANGPT2
|
SYNGAP1
|
MYH7
|
MUC1
|
IL10
|
MMP2
|
IL18
|
ELANE
|
TIMP1
|
MME
|
CD40
|
SERPINA1
|
MEF2C
|
IGF1
|
YRDC
|
TXN
|
LOX
|
NGB
|
CNR1
|
CKB
|
CASP3
|
ENO2
|
MTOR
|
JUN
|
FLNA
|
HTR2A
|
TTN
|
ADCYAP1
|
PLAT
|
NPPB
|
SMARCAL1
|
CTLA4
|
SLC8A1
|
THBS1
|
STAT3
|
CPT2
|
SMARCA4
|
F3
|
PLG
|
CP
|
ERCC2
|
TGIF1
|
TNNI3
|
COMT
|
MAPT
|
IL1RN
|
ADAMTS13
|
EGF
|
ANXA5
|
GDNF
|
MIF
|
ITGA2B
|
GFAP
|
ACTA2
|
SLC2A1
|
ADRB2
|
ITGAM
|
LAMB1
|
TNNT2
|
ADRB1
|
EDN1
|
SETD2
|
APOH
|
IDH1
|
CTSB
|
HSPG2
|
PCNA
|
OLR1
|
PSEN1
|
SERPINA3
|
PROC
|
LDLR
|
PLAU
|
MT-CO1
|
MBP
|
BGN
|
SERPINC1
|
PLA2G6
|
EGR1
|
APOA1
|
NES
|
RPS27A
|
NFKB1
|
FMR1
|
TLR4
|
KDR
|
IFNG
|
HSPB1
|
SLC12A2
|
ADIPOQ
|
XIAP
|
NOL3
|
HIF1A
|
PTGS2
|
VLDLR
|
ALOX5
|
SMAD2
|
IL1A
|
IL13
|
ENTPD1
|
PRNP
|
BAX
|
INS
|
SLC17A5
|
EGFR
|
NCF1
|
KCNMA1
|
SIRT1
|
CTNNB1
|
KNG1
|
AGT
|
PROCR
|
LEP
|
CDKN3
|
ABCA1
|
SRC
|
IL1B
|
SERPINI1
|
GRIN2A
|
THPO
|
NOTCH1
|
SH2B3
|
ITGB2
|
GLO1
|
COL3A1
|
CXCL12
|
ITGB3
|
PSAP
|
BAD
|
GAPDH
|
PLA2G7
|
CA2
|
CRP
|
GRIK2
|
HMGB1
|
FGA
|
STAT1
|
VCP
|
MAPK8IP1
|
ABCC8
|
COL4A2
|
GP1BA
|
CALCA
|
CLU
|
IL2
|
AOC3
|
ITGB1
|
PRKG1
|
BCL2
|
PIK3C2A
|
FGF2
|
NGF
|
BCL2L1
|
SST
|
CAMK2A
|
TIE1
|
BDNF
|
GSR
|
IL4
|
MAPK8
|
ESR1
|
GSS
|
TERT
|
CFLAR
|
XDH
|
CD36
|
ADORA2A
|
TIMP2
|
IKBKG
|
FGFR2
|
BMP6
|
PDE5A
|
NOS1
|
CDK5
|
MAPK1
|
MBL2
|
SMPD1
|
SDHB
|
DNM1L
|
MLC1
|
2.4 A total of 1095 genes of human urine stem cells were found in Genecars. Some genes are shown in Table 4:
Table 4
Human urine stem cells partial gene targets
Human urine stem cells partial gene targets
|
IL6
|
MUC4
|
UBA1
|
ACO1
|
NPHP3
|
EEF1G
|
SPPL2A
|
PROM2
|
KRAS
|
IGFBP2
|
PPT1
|
MGAT5
|
CDH16
|
DDAH1
|
CAPN7
|
FUCA2
|
TERT
|
C3
|
LAMP1
|
GNB3
|
PPT2
|
NID2
|
IST1
|
SECTM1
|
BRAF
|
NEU1
|
IRAK1
|
SERPINB9
|
LBP
|
LTBP2
|
KRT75
|
MYL6B
|
CD44
|
ANXA2
|
DMBT1
|
AQP2
|
CCT4
|
ANXA3
|
TUBB8
|
PEF1
|
CXCL12
|
TXN
|
TPI1
|
ACTR2
|
ACTN3
|
ATP6V1A
|
PYGB
|
STK25
|
FGFR3
|
YWHAE
|
NECTIN2
|
DKK3
|
CFD
|
H4C12
|
SERPINA6
|
H2AC16
|
ITGB1
|
STXBP2
|
MYH10
|
GPI
|
UMOD
|
COTL1
|
ARHGAP1
|
EHD4
|
CDH1
|
PLA2G2A
|
KL
|
SDCBP
|
EPX
|
STK26
|
MGAT1
|
LRRC57
|
FGF2
|
MMP7
|
HNRNPK
|
APRT
|
BAIAP2L1
|
UPK1A
|
CLEC3B
|
GATM
|
IL1B
|
SERPINA1
|
MTHFD1
|
ARF1
|
C8B
|
CFB
|
GNG4
|
C8A
|
CASP8
|
LGALS1
|
ARSB
|
FAT4
|
NPHS2
|
CA1
|
RAB21
|
MAN1C1
|
EGF
|
TUBB
|
H4-16
|
HNRNPM
|
SERPINF2
|
CACNA2D1
|
FIGNL1
|
DOP1B
|
FASLG
|
DNASE1
|
RDX
|
CETP
|
SLC12A1
|
NIBAN1
|
RAB11B
|
VPS25
|
MIR21
|
APOB
|
COL18A1
|
FGB
|
GSTM3
|
PYGM
|
TBC1D10A
|
GMPPA
|
CASP3
|
AQP1
|
CFL1
|
HMCN1
|
VPS4B
|
UGP2
|
SMS
|
PSMA8
|
PPARG
|
IGF2R
|
GP1BA
|
APOH
|
TUBB6
|
TXNDC5
|
PLPP1
|
H2AC17
|
ENG
|
FCGR3B
|
ARF6
|
CKB
|
FSHB
|
CAND1
|
ENO3
|
NUCB1
|
VCAM1
|
KLK3
|
PGK1
|
ENPEP
|
ATP5F1B
|
SERPINB8
|
ATP6V1B1
|
RAB5B
|
PROM1
|
KNG1
|
IGHG1
|
RBP4
|
SDCBP2
|
PACSIN3
|
NAPRT
|
PGM2
|
ABCB1
|
DMD
|
GAS6
|
FABP5
|
APOA2
|
PSMB2
|
ANXA7
|
GPD1L
|
HBB
|
CP
|
HSP90AB1
|
EFNB1
|
MACROH2A1
|
WASF3
|
CPVL
|
TNXA
|
FN1
|
PTPRJ
|
ACTG2
|
CSTB
|
MYOF
|
BASP1
|
COL15A1
|
PTTG1IP
|
CD36
|
CLTC
|
MB
|
LAMB2
|
SERPIND1
|
SERPING1
|
ACTR1A
|
ENTPD2
|
THY1
|
RPS27A
|
TLN1
|
GLO1
|
NIBAN2
|
GPLD1
|
LAP3
|
SPR
|
MMP9
|
KRT13
|
C5
|
HSPA1B
|
HPN
|
GLG1
|
FAM3C
|
MYO5C
|
EPCAM
|
TTR
|
LRP2
|
BST1
|
SFRP4
|
MYO1D
|
ATP6V0D1
|
H2AC6
|
MUC1
|
ACP1
|
CANX
|
GPX3
|
HRG
|
UPK3A
|
GCA
|
RNASE2
|
NF1
|
HBA2
|
YWHAZ
|
PRDX6
|
SELENOP
|
APCS
|
ARF3
|
ALDH1L2
|
ALB
|
RAB27A
|
LAMA5
|
MYO1C
|
ALDH9A1
|
ADH5
|
VPS4A
|
GUCA2B
|
RAC1
|
PRKACA
|
DAG1
|
AHCY
|
LILRB4
|
SUSD2
|
MXRA8
|
PPIC
|
MMP2
|
GSN
|
FGA
|
PIGR
|
GM2A
|
BTD
|
SULT2B1
|
H2AC13
|
SOD1
|
LAMA3
|
CNP
|
ALOX15B
|
GC
|
H2AZ1
|
AKR1C4
|
PLBD2
|
ANPEP
|
RXRA
|
IGFBP7
|
HPR
|
CST6
|
SORD
|
PROZ
|
MON2
|
SPP1
|
CFH
|
CD177
|
CLIC1
|
C1R
|
PAICS
|
QDPR
|
CTSZ
|
LHCGR
|
PODXL
|
CDH11
|
UBA52
|
MDH1
|
PAM
|
MLPH
|
NAAA
|
B2M
|
PRDX1
|
GGT1
|
AKR1C3
|
RHOG
|
H4C2
|
ACP2
|
CUTA
|
EDN1
|
KRT1
|
IGHM
|
ANO6
|
FBLN5
|
LTA4H
|
LUM
|
GSTT2
|
NT5E
|
PLG
|
COL4A2
|
PGM1
|
DSC1
|
MPI
|
H2AC4
|
CNDP2
|
SMO
|
ANXA1
|
CHI3L1
|
NID1
|
ARPC3
|
SERPINI1
|
DNPH1
|
XPNPEP1
|
ACTB
|
SERPINF1
|
CST3
|
FUCA1
|
PSME2
|
NPEPPS
|
AKR7A2
|
ATRN
|
CASP9
|
KRT20
|
CHL1
|
PSMA7
|
TUBB4B
|
H2AC20
|
CPNE2
|
ABHD14B
|
FCGR3A
|
SFN
|
PABPC1
|
GANAB
|
ACLY
|
SPON2
|
AOC1
|
BDH2
|
2.5 Venny diagram. The gene crossover between cerebral ischemia-reperfusion and human urine stem cells was analyzed, and 258 key targets of Venny diagram were obtained by deleting duplicates, as shown in Fig. 5:
2.6 Cross-concentration genes were searched on PubMed by key words
Key words "Cerebral ischemia reperfusion, Stem cell transplantation" were input on PubMed and CNQI to search genes. Genes reported and unreported in crosssets were screened and sorted into Excel tables. There are 258 intersection targets in the Venny diagram, among which 6 genes have been reported and 252 genes have not been reported, as shown in Table 5, 6, and 7:
Table 5
Cerebral ischemia reperfusion - Human urine stem cells
Cerebral ischemia reperfusion - Human urine stem cells
|
CST3
|
ENO2
|
TXN
|
PLAU
|
ABCB1
|
GOT2
|
CDC42
|
F2
|
ACTA2
|
CP
|
SMPD1
|
MUC1
|
TF
|
LTF
|
IL6
|
SERPINA3
|
EGF
|
HP
|
SERPINA1
|
C4A
|
ITGAV
|
ACE
|
KNG1
|
IDH1
|
MME
|
CKB
|
ACTC1
|
EPX
|
ENG
|
SERPINI1
|
APOA1
|
THBS1
|
COMT
|
SERPINF2
|
FABP1
|
SOD1
|
CXCL12
|
HSPB1
|
HSPG2
|
BGN
|
LRP2
|
PRDX1
|
MPO
|
GP1BA
|
PROCR
|
RPS27A
|
GLO1
|
FASLG
|
GGT1
|
CASP3
|
GSR
|
PSAP
|
GAPDH
|
SOD3
|
CTSG
|
SERPINA4
|
EDN1
|
CD36
|
FGA
|
VCP
|
AQP1
|
NT5E
|
CD55
|
SERPINC1
|
CASP9
|
CLU
|
GSS
|
PROS1
|
HSP90AA1
|
SERPINF1
|
IL1B
|
PON1
|
CTSD
|
ACTB
|
PLA2G2A
|
GDF15
|
TKT
|
COL4A2
|
PLG
|
FGB
|
FN1
|
COL18A1
|
RETN
|
NID1
|
MMP9
|
APOH
|
HSPA8
|
MIF
|
AKR1B1
|
LGALS3
|
AHSG
|
SOD2
|
AGT
|
MIR146A
|
ITGB1
|
RAC1
|
ACE2
|
PTGDS
|
MIR21
|
FGF2
|
PPARG
|
TERT
|
LCN2
|
NAXE
|
GNA11
|
CAT
|
APOB
|
TIMP1
|
FABP3
|
C3
|
PNP
|
CD14
|
ALB
|
HSPA1A
|
FLNA
|
CTSL
|
NAGLU
|
SLC9A3R2
|
CHI3L1
|
MB
|
G6PD
|
ANXA5
|
PARK7
|
CASP8
|
ACP1
|
C5
|
MMP2
|
VCAM1
|
ITGAM
|
SPP1
|
CFH
|
KL
|
ALDH9A1
|
ELANE
|
CR1
|
CTSB
|
ACTG1
|
IGFBP2
|
CD44
|
AOC1
|
KRT18
|
GUSB
|
AXL
|
PPIA
|
CD38
|
MYH10
|
LIFR
|
DNM2
|
S100A8
|
MGAM
|
MASP2
|
HMCN1
|
THY1
|
APOC3
|
VTN
|
GPX3
|
PROM1
|
LDHA
|
PSMA7
|
ENTPD2
|
S100A9
|
GSTP1
|
C1R
|
LRG1
|
ALDOA
|
YWHAZ
|
UBE2D3
|
HPX
|
ENO1
|
AGRN
|
TNXB
|
HSPA1B
|
SELENOP
|
ATP5F1A
|
APRT
|
CAPN1
|
NEU1
|
TPI1
|
GSTA2
|
HSP90AB1
|
DBI
|
IL6ST
|
NAMPT
|
APOD
|
RNASE3
|
SI
|
PRDX6
|
WWP2
|
LBP
|
CA1
|
FCGR3A
|
F12
|
PRKACA
|
ENO3
|
ACTA1
|
COL6A1
|
CRYAB
|
EPHX2
|
PLSCR1
|
CANT1
|
SAA4
|
HRG
|
NPR3
|
FCGR3B
|
H2AX
|
A2M
|
GSTT1
|
DDAH2
|
ACTN4
|
GC
|
CD59
|
CPB2
|
DDAH1
|
IGFBP7
|
FASN
|
LAP3
|
ANXA7
|
DES
|
IRAK1
|
CEACAM1
|
COL6A3
|
CFB
|
GSTM3
|
AMBP
|
DPP4
|
EEF2
|
GOT1
|
CLEC3B
|
UMOD
|
VPS28
|
SERPING1
|
PTPA
|
TOLLIP
|
LGALS1
|
LAMC1
|
SFN
|
FSTL1
|
PRDX2
|
B2M
|
CUBN
|
PRDX5
|
LAMB2
|
CEACAM5
|
CBR1
|
ITCH
|
TGM2
|
ANXA2
|
SAA1
|
FABP4
|
PEPD
|
SELENBP1
|
SLC3A2
|
ANXA1
|
IQGAP1
|
VDAC1
|
THBS4
|
DEFA1
|
ART3
|
|
Table 6
Gene list was reported after query
Gene list was reported after query
|
IL6
|
IL1B
|
MPO
|
SOD1
|
MMP9
|
CAT
|
Table 7
No gene list was reported after query
No gene list was reported after query
|
CST3
|
ENO2
|
TXN
|
PLAU
|
ABCB1
|
GOT2
|
CDC42
|
F2
|
ACTA2
|
CP
|
SMPD1
|
MUC1
|
TF
|
LTF
|
ACE
|
SERPINA3
|
EGF
|
HP
|
SERPINA1
|
C4A
|
ITGAV
|
ENG
|
KNG1
|
IDH1
|
MME
|
CKB
|
ACTC1
|
EPX
|
CASP3
|
SERPINI1
|
APOA1
|
THBS1
|
COMT
|
SERPINF2
|
FABP1
|
EDN1
|
CXCL12
|
HSPB1
|
HSPG2
|
BGN
|
LRP2
|
PRDX1
|
SERPINC1
|
GP1BA
|
PROCR
|
RPS27A
|
GLO1
|
FASLG
|
GGT1
|
COL4A2
|
GSR
|
PSAP
|
GAPDH
|
SOD3
|
CTSG
|
SERPINA4
|
SOD2
|
CD36
|
FGA
|
VCP
|
AQP1
|
NT5E
|
CD55
|
MIR21
|
CASP9
|
CLU
|
GSS
|
PROS1
|
HSP90AA1
|
SERPINF1
|
ALB
|
PON1
|
CTSD
|
ACTB
|
PLA2G2A
|
GDF15
|
TKT
|
MB
|
PLG
|
FGB
|
FN1
|
COL18A1
|
RETN
|
NID1
|
MMP2
|
APOH
|
HSPA8
|
MIF
|
AKR1B1
|
LGALS3
|
AHSG
|
ELANE
|
AGT
|
MIR146A
|
ITGB1
|
RAC1
|
ACE2
|
PTGDS
|
AOC1
|
FGF2
|
PPARG
|
TERT
|
LCN2
|
NAXE
|
GNA11
|
S100A9
|
APOB
|
TIMP1
|
FABP3
|
C3
|
PNP
|
CD14
|
IL6ST
|
HSPA1A
|
FLNA
|
CTSL
|
NAGLU
|
SLC9A3R2
|
CHI3L1
|
NPR3
|
G6PD
|
ANXA5
|
PARK7
|
CASP8
|
ACP1
|
C5
|
AMBP
|
VCAM1
|
ITGAM
|
SPP1
|
CFH
|
KL
|
ALDH9A1
|
CR1
|
CTSB
|
ACTG1
|
IGFBP2
|
CD44
|
MYH10
|
TGM2
|
KRT18
|
GUSB
|
AXL
|
PPIA
|
CD38
|
THY1
|
ANXA1
|
DNM2
|
S100A8
|
MGAM
|
MASP2
|
HMCN1
|
ENTPD2
|
LIFR
|
VTN
|
GPX3
|
PROM1
|
LDHA
|
PSMA7
|
UBE2D3
|
APOC3
|
GSTP1
|
C1R
|
LRG1
|
ALDOA
|
YWHAZ
|
ATP5F1A
|
ANXA2
|
ENO1
|
AGRN
|
TNXB
|
HSPA1B
|
SELENOP
|
DBI
|
IQGAP1
|
CAPN1
|
NEU1
|
TPI1
|
GSTA2
|
HSP90AB1
|
WWP2
|
HPX
|
NAMPT
|
APOD
|
RNASE3
|
SI
|
PRDX6
|
ACTA1
|
APRT
|
CA1
|
FCGR3A
|
F12
|
PRKACA
|
ENO3
|
HRG
|
SAA1
|
CRYAB
|
EPHX2
|
PLSCR1
|
CANT1
|
SAA4
|
ACTN4
|
VDAC1
|
FCGR3B
|
H2AX
|
A2M
|
GSTT1
|
DDAH2
|
LAP3
|
LBP
|
CD59
|
CPB2
|
DDAH1
|
IGFBP7
|
FASN
|
GSTM3
|
COL6A1
|
DES
|
IRAK1
|
CEACAM1
|
COL6A3
|
CFB
|
VPS28
|
FABP4
|
DPP4
|
EEF2
|
GOT1
|
CLEC3B
|
UMOD
|
FSTL1
|
THBS4
|
PTPA
|
TOLLIP
|
LGALS1
|
LAMC1
|
SFN
|
CBR1
|
GC
|
B2M
|
CUBN
|
PRDX5
|
LAMB2
|
CEACAM5
|
SELENBP1
|
ANXA7
|
SLC3A2
|
PRDX2
|
SERPING1
|
ITCH
|
DEFA1
|
ART3
|
PEPD
|
2.6 Cross-concentration genes were searched on PubMed by key words
To elucidate the mechanism of human urine stem cells on cerebral ischemia-reperfusion, we analyzed GOGO enrichment of human urine stem cell genes extracted during cerebral ischemia-reperfusion. As shown in the figure, the top 10 biological processes (BPS) involved in GOGO enrichment analysis are as follows: Neutrophil activation involved in immune response, neutrophil degranulation, Hemostasis, blood coagulation, negative regulation of coagulation, regulation of coagulation endopeptidase activity Regulation of Peptidase activity. The top 10 factors involved in cell component (CC) in GOGO enrichment analysis were: Vesicle Lumen, Cytoplasmic Vesicle Lumen, Secretory Granule Lumen, Collagen − containing extracellular matrix, blood Microparticle, vacuolar Lumen, platelet alpha granule lumen, platelet alpha granule, endoplasmic reticulum Lumen, Ficolin − 1 − Rich Granule. The top 10 factors involved in molecular function (MF) in GOGO enrichment analysis were enzyme inhibitor activity, Endopeptidase inhibitor activity and Peptidase regulator Activity, Peptidase inhibitor activity Endopeptidase regulator activity, Sulfur compound binding, Glycosaminoglycan binding, Antioxidant activity, Heparin Binding, Extracellular matrix structural constituent and Protease binding are shown in Fig. 6. Figure 6 shows that BP participates in many biological processes, among which neutrophil degranulation is the most abundant biological process. Neutrophil activation involved in immune response, and platelet degranulation. These biological processes constitute an important part of cell development.CC involves many cellular components, among which Vesicle Lumen is the most important chemical component, followed by Cytoplasmic Vesicle Lumen and Secretory granule Lumen, which constitute cellular components related to cell development. MF involves many molecular characteristics, among which enzyme inhibitor activity is one of the most important, followed by endopeptidase inhibitor activity, Peptidase regulator activity, these molecules constitute molecular functions related to cell development (Fig. 6).
2.8 KEGG pathway analysis
To elucidate the mechanism of human urine stem cells on cerebral ischemia-reperfusion, we analyzed the KEGG pathway after gene crossover (Fig. 7, Table 8). The results showed that the top 10 pathways analyzed by KEGG pathway were: Complement and coagulation cascades, ECM-receptor interaction, Glutathione metabolism, Proteoglycans in Cancer, Legionellosis,
Lipid and atherosclerosis, Staphylococcus aureus infection, Amoebiasis,
Fluid shear stress and atherosclerosis.
Table 8
Top 10 pathways of KEGG pathway
Expression of KEGG pathway
|
ID
|
Description
|
P value
|
p.adjust
|
Q value
|
Count
|
hsa04610
|
Complement and coagulation cascades
|
2.51E-24
|
6.83E-22
|
5.00E-22
|
28
|
hsa04512
|
ECM-receptor interaction
|
5.03E-12
|
6.84E-10
|
5.00E-10
|
18
|
hsa00480
|
Glutathione metabolism
|
1.76E-08
|
1.59E-06
|
1.17E-06
|
12
|
hsa05205
|
Proteoglycans in cancer
|
4.91E-08
|
3.34E-06
|
2.44E-06
|
21
|
hsa05134
|
Legionellosis
|
1.51E-07
|
7.66E-06
|
5.61E-06
|
11
|
hsa04510
|
Focal adhesion
|
1.69E-07
|
7.66E-06
|
5.61E-06
|
20
|
hsa05417
|
Lipid and atherosclerosis
|
5.07E-07
|
1.97E-05
|
1.44E-05
|
20
|
hsa05150
|
Staphylococcus aureus infection
|
8.33E-07
|
2.83E-05
|
2.07E-05
|
13
|
hsa05146
|
Amoebiasis
|
1.69E-06
|
5.10E-05
|
3.73E-05
|
13
|
hsa05418
|
Fluid shear stress and atherosclerosis
|
2.28E-06
|
6.20E-05
|
4.54E-05
|
15
|
Note: ID is the KEGG pathway ID, description is the KEGG pathway name description, count is the number of targets on the corresponding KEGG pathway, P value is the assumed value, and p.adjust and Q value are the assumed values after FDR (false discovery rate) correction. |
2.9 PPI protein interaction and analysis
2.9.1 252 intersecting genes not reported in Table 5 were selected as String (https://string-db.org/)After UniProt Transformation), and protein interaction network analysis was performed to understand intermolecular interactions and protein interaction network diagrams. See Fig. 8 and Table 9. Each node represents a protein target, and each connector represents the interaction between two target proteins. The larger the node, the higher the centrality of the protein target, the thicker the connecting line, and the stronger the interaction between the two proteins.
As shown in Fig. 8, it can be seen that there are many histones and there are complex relationships among genes. Mainly in a circular concentrated in the middle of the protein. Secondly, there is a protein relationship formed at the upper right. There is also a small amount of protein in the upper and lower left.
Table 9
Relationship between cerebral ischemia reperfusion and human urine stem cell protein
Relationship between cerebral ischemia reperfusion and human urine stem cell protein
|
#node1
|
node2
|
Co-expression
|
experimentally determined interaction
|
Database-annotated
|
Automatic text mining
|
Combined score
|
A2M
|
CPB2
|
0.159
|
0.27
|
0
|
0.458
|
0.638
|
A2M
|
APOH
|
0.141
|
0
|
0
|
0.519
|
0.569
|
A2M
|
MIF
|
0
|
0
|
0
|
0.459
|
0.459
|
A2M
|
CTSG
|
0
|
0.351
|
0
|
0.607
|
0.734
|
A2M
|
TIMP1
|
0.062
|
0
|
0
|
0.596
|
0.605
|
A2M
|
MMP2
|
0.133
|
0.632
|
0.6
|
0.57
|
0.937
|
A2M
|
VTN
|
0.111
|
0
|
0
|
0.503
|
0.539
|
A2M
|
APOC3
|
0.117
|
0
|
0
|
0.414
|
0.46
|
A2M
|
GAPDH
|
0
|
0.282
|
0
|
0.301
|
0.476
|
A2M
|
HRG
|
0.145
|
0.102
|
0
|
0.522
|
0.601
|
2.9.2 Search 252 intersected genes in Gennecars, including Symbol, Description, CateGOry, GIFtS, GC ID and Score. The top 10 genes corresponding to the screened Sore are shown in Table 10. The protein interaction network analysis is conducted to understand the interaction between molecules and the protein interaction network diagram. See Fig. 9 and Table 11. Each node represents a protein target, and each connector represents the interaction between two target proteins. The larger the node, the higher the centrality of the protein target, the thicker the connecting line, and the stronger the interaction between the two proteins.
Table 10
The gene with the highest Score
The gene with the highest Score
|
Symbol
|
Description
|
CateGOry
|
GIFtS
|
GC id
|
Score
|
G6PD
|
Glucose-6-Phosphate Dehydrogenase
|
Protein Coding
|
48
|
GC0XM154531
|
114.67
|
C3
|
Complement C3
|
Protein Coding
|
47
|
GC19M006677
|
112.17
|
CD59
|
CD59 Molecule (CD59 Blood Group)
|
Protein Coding
|
45
|
GC11M033704
|
111.51
|
CD36
|
CD36 Molecule
|
Protein Coding
|
47
|
GC07P080369
|
110.13
|
CD44
|
CD44 Molecule (Indian Blood Group)
|
Protein Coding
|
46
|
GC11P035139
|
99.13
|
ACE
|
Angiotensin I Converting Enzyme
|
Protein Coding
|
50
|
GC17P063477
|
88.23
|
CD14
|
CD14 Molecule
|
Protein Coding
|
45
|
GC05M140631
|
84.36
|
RAC1
|
Rac Family Small GTPase 1
|
Protein Coding
|
48
|
GC07P006377
|
84.23
|
APOB
|
Apolipoprotein B
|
Protein Coding
|
45
|
GC02M020956
|
84.19
|
CD55
|
CD55 Molecule (Cromer Blood Group)
|
Protein Coding
|
46
|
GC01P207321
|
83.87
|
Figure 6 shows the PPI protein interaction diagram. It can be seen from the diagram that among the 10 genes with the largest Sore value, C3 and CD44 are core genes, C3 is associated with ACE, APOB, CD55 and CD59, and CD44 is associated with CD55, CD59, CD14 and RAC1. However, the relationship between them is ACE: APOB, ACE: C3, APOB: C3, APOB: CD36, C3: CD59, C3: CD55, CD14: CD44, CD14: CD36, CD44: RAC1, CD44: CD55, CD44: CD59, CD55: CD59
Table 11
PPI protein interaction table of the first 10 genes
PPI protein interaction table of the first 10 genes
|
|
|
#node1
|
node2
|
Co-expression
|
experimentally determined interaction
|
Database annotated
|
Automatic text mining
|
Combined score
|
ACE
|
APOB
|
0.063
|
0
|
0
|
0.609
|
0.617
|
ACE
|
C3
|
0.071
|
0
|
0
|
0.393
|
0.412
|
APOB
|
C3
|
0.166
|
0
|
0
|
0.47
|
0.539
|
APOB
|
CD36
|
0.062
|
0.27
|
0.6
|
0.432
|
0.823
|
C3
|
CD59
|
0.058
|
0
|
0
|
0.739
|
0.743
|
C3
|
CD55
|
0
|
0.8
|
0.6
|
0.977
|
0.998
|
CD14
|
CD44
|
0.088
|
0
|
0
|
0.49
|
0.515
|
CD14
|
CD36
|
0.182
|
0
|
0
|
0.443
|
0.525
|
CD44
|
RAC1
|
0
|
0
|
0.9
|
0.283
|
0.925
|
CD44
|
CD55
|
0.065
|
0
|
0
|
0.451
|
0.464
|
CD44
|
CD59
|
0.07
|
0
|
0
|
0.507
|
0.521
|
CD55
|
CD59
|
0
|
0
|
0.5
|
0.915
|
0.955
|